Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity

被引：50

作者：

Chetan, Bhadaliya ^{[1
]}

Bunha, Mahesh ^{[1
]}

Jagrat, Monika ^{[1
]}

Sinha, Barij Nayan ^{[1
]}

Saiko, Philipp ^{[1
]}

Graser, Geraldine ^{[2
]}

Szekeres, Thomas ^{[2
]}

Raman, Ganapathy ^{[3
]}

Rajendran, Praveen ^{[3
]}

Moorthy, Dhatchana ^{[3
]}

Basu, Arijit ^{[1
]}

Jayaprakash, Venkatesan ^{[1
]}

机构：

[1] Birla Inst Technol, Dept Pharmaceut Sci, Ranchi 835215, Jharkhand, India

[2] Gen Hosp Vienna Med Univ Vienna, Dept Med & Chem Lab Diagnost, A-1090 Vienna, Austria

[3] Orchid Res Labs Ltd, Madras 600119, Tamil Nadu, India

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 13期

关键词：

Histone deacetylase inhibitors; Piperazine linker; Hydroxamates; RR pharmacophore; ASSAY; AGENTS; PROLIFERATION;

D O I：

10.1016/j.bmcl.2010.05.020

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Six compounds were synthesized with piperazine in linker region and hydroxamate as Zinc Binding Group ( ZBG). They were screened against three cancer cell-lines (NCIH460; HCT116; U251). Compounds 5c and 5f with GI(50) value of 9.33 +/- 1.3 mu M and 12.03 +/- 4 mu M, respectively, were tested for their inhibitory potential on hHDAC8. Compound 5c had IC(50) of 33.67 mu M. Compounds were also screened for their anticancer activity against HL60 human promyelocytic leukemia cell line due to the presence of pharmacophoric features of RR inhibitors in them. Compound 5c had IC(50) of 0.6 mu M at 48 h. (c) 2010 Elsevier Ltd. All rights reserved.

引用

页码：3906 / 3910

页数：5

共 50 条

[11] Chemical Tools for Probing Histone Deacetylase (HDAC) Activity
Minoshima, Masafumi
Kikuchi, Kazuya
ANALYTICAL SCIENCES, 2015, 31 (04) : 287 - 292
[12] Design and Synthesis of Topoisomerases-Histone Deacetylase Dual Targeted Quinoline-Bridged Hydroxamates as Anticancer Agents
Joshi, Gaurav
Yadav, Umesh Prasad
Rafiq, Zahid
Grewal, Preeti
Kumar, Manvendra
Singh, Tashvinder
Jha, Vibhu
Sharma, Praveen
Eriksson, Leif A.
Srinivas, Lenkalapelly
Dahibhate, Nilesh Lakshman
Srivastava, Pratima
Bhutani, Priyadeep
Mishra, Uttam Kumar
Sharon, Ashoke
Banerjee, Uttam C.
Sharma, Nisha
Chatterjee, Joydeep
Tikoo, Kulbhushan
Singh, Sandeep
Kumar, Raj
JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 2849 - 2868
[13] Chemical Tools for Probing Histone Deacetylase (HDAC) Activity
Masafumi Minoshima
Kazuya Kikuchi
Analytical Sciences, 2015, 31 : 287 - 292
[14] Novel Pyridine-Based Hydroxamates and 2′-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity
Zwergel, Clemens
Di Bello, Elisabetta
Fioravanti, Rossella
Conte, Mariarosaria
Nebbioso, Angela
Mazzone, Roberta
Brosch, Gerald
Mercurio, Ciro
Varasi, Mario
Altucci, Lucia
Valente, Sergio
Mai, Antonello
CHEMMEDCHEM, 2021, 16 (06) : 989 - 999
[15] Synthesis of oxazoline hydroxamates α,β-unsaturated: Cytotoxic evaluation and inhibitory activity in vitro of histone deacetylases
Carrizales-Castillo, Juan J. J.
Camacho-Corona, Maria del Rayo
Hernandez-Fernandez, Eugenio
Heredia-Nunez, Leonardo Adolfo
Lagunas-Rivera, Selene
Rios, Maria Yolanda
Arredondo-Espinoza, Eder
Avalos-Alanis, Francisco G.
RESULTS IN CHEMISTRY, 2025, 14
[16] HISTONE DEACETYLASE INHIBITORY ACTIVITY OF VALPROIC ACID IN GLIOBLASTOMA
Chang, A. R.
Kim, I. H.
Park, C. I.
RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S476 - S476
[17] Histone deacetylase inhibitory activity of valproic acid in glioblastoma
Chang, A.
Kim, I.
Park, C.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S240 - S241
[18] Impact of methyleugenol and selected methyleugenol metabolites on histone deacetylase (HDAC) activity and HDAC expression
Groh, I. A. M.
Loeschmann, T.
Rudakovski, O.
Esselen, M.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S28 - S28
[19] Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers
Niegisch, Guenter
Knievel, Judith
Koch, Annemarie
Hader, Christiane
Fischer, Ute
Albers, Peter
Schulz, Wolfgang A.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (08) : 1770 - 1779
[20] Design, synthesis and antitumor activity evaluation of benzimidazole derivatives with potent HDAC inhibitory activity
Ping, Jiantao
Chu, Hongrui
Zhao, Yisheng
Chen, Chen
MEDICINAL CHEMISTRY RESEARCH, 2025, 34 (02) : 445 - 454

← 1 2 3 4 5 →